J&J gets first-of-its-kind prostate cancer approval Submitted by admin on Wed, 02/14/2018 - 23:48 Read more about J&J gets first-of-its-kind prostate cancer approval Source Biopharma Dive Headline J&J gets first-of-its-kind prostate cancer approval News Tags JNJ apalutamide prostate cancer
As CAR-Ts go from candidates to brands, what's the marketing strategy? Submitted by admin on Tue, 02/13/2018 - 09:01 Read more about As CAR-Ts go from candidates to brands, what's the marketing strategy? Source Medical Marketing and Media Headline As CAR-Ts go from candidates to brands, what's the marketing strategy? News Tags CAR-T drug marketing JCAR017 Juno Therapeutics Celgene bb2121 Bluebird Bio apalutamide Janssen
Strong data lift profile of J&J's cancer drug apalutamide Submitted by admin on Tue, 02/06/2018 - 11:45 Read more about Strong data lift profile of J&J's cancer drug apalutamide Source Biopharma Dive Headline Strong data lift profile of J&J's cancer drug apalutamide News Tags JNJ apalutamide prostate cancer
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK Submitted by admin on Thu, 01/18/2018 - 10:00 Read more about With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK Source Endpoints Headline With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles f… News Tags Pfizer JNJ patents Zytiga Xtandi prostate cancer apalutamide
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate Submitted by admin on Sun, 12/17/2017 - 11:47 Read more about The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate Source Endpoints Headline The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate News Tags drug launches Bictegravir/F/TAF Gilead Sciences semaglutide Novo Nordisk epacadostat Incyte Rova-T AbbVie ozanimod Celgene apalutamide JNJ Elagolix AVXS-101 AveXis lanadelumab Shire Epidiolex GW Pharma
J&J takes another big step forward with next-gen prostate cancer blockbuster apalutamide Submitted by admin on Thu, 10/12/2017 - 09:16 Read more about J&J takes another big step forward with next-gen prostate cancer blockbuster apalutamide Source Endpoints Headline J&J takes another big step forward with next-gen prostate cancer blockbuster ap… News Tags JNJ prostate cancer apalutamide
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet Submitted by admin on Sun, 07/23/2017 - 11:47 Read more about These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet Source Motley Fool Headline These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market … News Tags Biogen aducanumab JNJ apalutamide Eli Lilly abemaciclib AbbVie Rova-T Celgene ozanimod